TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, consistent release of chemotherapy proved far more effective than traditional short-term treatments. The therapy may…
A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists - the class of drugs behind Ozempic, Wegovy and Mounjaro, for example - may do more than regulate blood sugar…
…as 60 cancer patients benefit from Medicaid Foundation’s ₦100m fund Dr. Zainab Shinkafi-Bagudu, President-elect of the Union for International Cancer Control (UICC), has called for increased collaboration between government, the
A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists—the class of drugs behind Ozempic, Wegovy and Mounjaro, for example—may do more than regulate blood sugar and…
The U.S. Food and Drug Administration has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer, following encouraging results from a clinical trial led in part by the University of Oklahoma Health…
NEW DELHI: Servier India, the Indian arm of the French pharmaceutical group Servier, has launched a patient-centric biomarker testing initiative in collaboration with leading genomic laboratories MedGenome and Strand Life Sciences.
Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says one more factor should be considered – chronological age.
Researchers from Rutgers Cancer Institute, New Jersey's only National Cancer Institute (NCI) - designated Comprehensive Cancer Center, and RWJBarnabas Health, along with colleagues from the National Cancer Institute, a center of the…
Dr. Matthew Rettig and his research team have been awarded a Clinical Cancer Research Center grant from the U.S. Department of Veterans Affairs to establish a new clinical cancer research center that will expand access to precision…
While some risk factors for cancer can be mitigated through lifestyle choices such as diet or exercise, aging is not one of them. In the case of pancreatic cancer, it also can limit treatment options if a patient is too frail to be safely…
(MedPage Today) -- Use of proton pump inhibitors (PPIs) alongside anti-cancer agents was associated with worse survival outcomes in patients with breast cancer, according to an observational study.
Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says one more factor should be considered—chronological age.
While some risk factors for cancer can be mitigated through lifestyle choices such as diet or exercise, aging is not one of them. In the case of pancreatic cancer, it also can limit treatment options if a patient is too frail to be safely…
Routine screening is limited to only a few cancer types. New research indicates that routine liquid biopsy testing (multi-cancer early detection testing) could substantially reduce late-stage cancer diagnoses, allowing patients to receive…